These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15199530)

  • 1. Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: preliminary results of a phase II and pharmacogenomic study.
    Estévez LG; Sánchez-Rovira P; Dómine M; León A; Calvo I; Jaén A; Casado V; Rubio G; Daz M; Miró C; Lobo F
    Semin Oncol; 2004 Apr; 31(2 Suppl 5):31-6. PubMed ID: 15199530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study.
    Estévez LG; Sánchez-Rovira P; Dómine M; León A; Calvo I; Jaén A; Casado V; Rubio G; Díaz M; Miró C; Lobo F; Carrasco E; Casillas M; San Antonio B
    Clin Transl Oncol; 2007 May; 9(5):317-22. PubMed ID: 17525042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial.
    Schmid P; Krocker J; Schulz CO; Michniewicz K; Dieing A; Eggemann H; Heilmann V; Blohmer JU; Sezer O; Elling D; Possinger K
    Anticancer Drugs; 2005 Jan; 16(1):21-9. PubMed ID: 15613900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial.
    Schmid P; Krocker J; Jehn C; Michniewicz K; Lehenbauer-Dehm S; Eggemann H; Heilmann V; Kümmel S; Schulz CO; Dieing A; Wischnewsky MB; Hauptmann S; Elling D; Possinger K; Flath B
    Ann Oncol; 2005 Oct; 16(10):1624-31. PubMed ID: 16030028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC.
    Halim A; Wahba H
    Med Oncol; 2012 Jun; 29(2):454-8. PubMed ID: 21350875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).
    McCarthy N; Boyle F; Zdenkowski N; Bull J; Leong E; Simpson A; Kannourakis G; Francis PA; Chirgwin J; Abdi E; Gebski V; Veillard AS; Zannino D; Wilcken N; Reaby L; Lindsay DF; Badger HD; Forbes JF;
    Breast; 2014 Apr; 23(2):142-51. PubMed ID: 24393617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.
    Yardley DA; Peacock NW; Dickson NR; White MB; Vázquez ER; Foust JT; Grapski R; Hendricks LK; Scott WL; Hainsworth JD
    Clin Breast Cancer; 2010 Jun; 10(3):217-23. PubMed ID: 20497920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.
    Medioni J; Huchon C; Le Frere-Belda MA; Hofmann H; Bats AS; Eme D; Andrieu JM; Oudard S; Lecuru F; Levy E
    Drugs R D; 2011; 11(2):147-57. PubMed ID: 21679005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer: preliminary results from a phase II trial.
    Pelegrí A; Calvo L; Mayordomo JI; Florián J; Vázquez S; Arcusa A; Martn-Richard M; Bayo JL; Virizuela J; Carrasco E; Antón A;
    Semin Oncol; 2004 Apr; 31(2 Suppl 5):20-4. PubMed ID: 15199528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer.
    Artioli G; Mocellin S; Borgato L; Cappetta A; Bozza F; Zavagno G; Zovato S; Marchet A; Pastorelli D
    Anticancer Res; 2010 Sep; 30(9):3817-21. PubMed ID: 20944176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.
    Kontopodis E; Kentepozidis N; Christophyllakis Ch; Boukovinas I; Kalykaki A; Kalbakis K; Vamvakas L; Agelaki S; Kotsakis A; Vardakis N; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):153-60. PubMed ID: 25398698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial.
    Laufman LR; Spiridonidis CH; Pritchard J; Roach R; Zangmeister J; Larrimer N; Moore T; Segal M; Jones J; Patel T; Gutterman L; Carman L; Colborn D; Kuebler JP
    Ann Oncol; 2001 Sep; 12(9):1259-64. PubMed ID: 11697837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial.
    Murialdo R; Bertolotti F; Pastorino G; Mencoboni M; Bergaglio M; Folco U; Cinzia N; Vaira F; Simoni C; Canobbio L; Parodi M; Brema F; Ballestrero A
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1009-16. PubMed ID: 21327683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: final results of a phase II trial.
    Pelegrí A; Calvo L; Antón A; Mayordomo JI; Florián J; Vásquez S; Arcusa A; Martín-Richard M; Bayo JL; Carrasco E; Virizuela J;
    Clin Breast Cancer; 2005 Dec; 6(5):433-8. PubMed ID: 16381627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer.
    O'Shaughnessy JA; Pluenneke R; Sternberg J; Khandelwal P; Ilegbodu D; Asmar L
    Clin Breast Cancer; 2006 Feb; 6(6):505-10. PubMed ID: 16595033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II Trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast cancer patients.
    Sánchez-Muñoz A; Dueñas-García R; Jaén-Morago A; Carrasco E; Chacón I; García-Tapiador AM; Ortega-Granados AL; Martínez-Ortega E; Ribelles N; Fernández-Navarro M; de la Torre-Cabrera C; Dueñas B; Rueda AI; Martínez J; Tortosa CR; Martín-Salvago MD; Sánchez-Rovira P
    Am J Clin Oncol; 2010 Oct; 33(5):432-7. PubMed ID: 19952716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
    Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
    Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study.
    Mavroudis D; Malamos N; Polyzos A; Kouroussis Ch; Christophilakis Ch; Varthalitis I; Androulakis N; Kalbakis K; Milaki G; Georgoulias V;
    Oncology; 2004; 67(3-4):250-6. PubMed ID: 15557786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study.
    Neri B; Vannini L; Giordano C; Grifoni R; Pantaleo P; Baldazzi V; Crisci A; Lapini A; Raugei A; Carini M
    Anticancer Drugs; 2007 Nov; 18(10):1207-11. PubMed ID: 17893522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
    Rastogi P; Buyse ME; Swain SM; Jacobs SA; Robidoux A; Liepman MK; Pajon ER; Dy PA; Posada JG; Melnik MK; Piette F; Geyer CE; Mamounas EP; Wolmark N
    Clin Breast Cancer; 2011 Aug; 11(4):228-34. PubMed ID: 21684812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.